Ashurst advises UBS and DBS on the Hong Kong IPO of Pioneer Pharma
Ashurst has advised UBS and DBS in connection with the US$180 million Hong Kong initial public offering of China Pioneer Pharma Holdings Limited. Pioneer Pharma is a leading marketing and promotion services provider for imported pharmaceutical products with a distribution network that covers over 7,500 hospitals and 40,000 drugstores in China.
UBS acted as sole global coordinator and sole sponsor in connection with the transaction, and UBS and DBS acted as joint bookrunners and joint lead managers.